Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeN95 Respirators3M Issues Statement in Response to the Announcements Issued by the White...

3M Issues Statement in Response to the Announcements Issued by the White House Last Evening

MARKET REPORTS

Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets – ResearchAndMarkets.com

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Global Electrophysiology Market (2021 to 2026) – Growth, Trends , COVID-19 Impact and Forecasts – ResearchAndMarkets.com

The Electrophysiology Market is expected to register a CAGR of 8.5% during the forecast period.

3M, over the last several weeks and months, and its employees have gone above and beyond to manufacture as many N95 respirators as possible for the U.S. market. Yesterday, the Administration formally invoked the Defense Production Act (DPA) to require 3M to prioritize orders from the Federal Emergency Management Agency (FEMA) for our N95 respirators.

3M notes they have been working closely with the Administration to do exactly that, and we appreciate the authorities in the DPA that provide a framework for us to expand even further the work we are doing in response to the global pandemic crisis. We look forward to working with FEMA to implement yesterday’s order.

In the course of our collaboration with the Administration this past weekend, the Administration requested that 3M increase the amount of respirators we currently import from our overseas operations into the U.S. We appreciate the assistance of the Administration to do exactly that. For example, earlier this week, we secured approval from China to export to the U.S. 10 million N95 respirators manufactured by 3M in China.

The Administration also requested that 3M cease exporting respirators that we currently manufacture in the United States to the Canadian and Latin American markets. There are, however, significant humanitarian implications of ceasing respirator supplies to healthcare workers in Canada and Latin America, where we are a critical supplier of respirators. In addition, ceasing all export of respirators produced in the United States would likely cause other countries to retaliate and do the same, as some have already done. If that were to occur, the net number of respirators being made available to the United States would actually decrease. That is the opposite of what we and the Administration, on behalf of the American people, both seek.

We also continue to act on reports of price gouging and unauthorized reselling related to 3M respirators. This activity is unethical and illegal. We are working with the U.S. Attorney General and attorneys general of every state, making it clear that 3M has not and will not raise prices for respirators and offering our assistance in the fight.

We look forward to working closely with the Administration to implement yesterday’s DPA order. We will continue to maximize the amount of respirators we can produce on behalf of U.S. healthcare workers, as we have every single day since this crisis began.

spot_img

DON'T MISS

AMRA Medical’s Whole-body MRI Analysis Used in FSHD Clinical Trial Research Network Study for Biomarker Development

To date, the MOVE study has used functional tests as primary outcomes, but recent studies have shown the promise of MRI for FSHD.

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Koya Medical Presents Positive Interim Data from Randomized Trial Comparing its Dayspring Lymphedema Treatment to Pneumatic Compression

For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.

18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA

“We have observed minimal slow-flow phenomena, seen with other paclitaxel drug-eluting balloons.  We have observed several cases of fast wound healing with SELUTION SLR. It is easy to track and deliver. We are looking forward to gaining further clinical experience with this device,” commented Prof. Chong.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy